

Amendments to the specification:

Rewrite page 3, line 13, to page 7, line 2, as:

The invention ~~defined~~ described in ~~Claim 1~~ of the present application provides a method of amplifying a target RNA containing a specific base sequence in a sample by an RNA amplification procedure which comprises a step of forming a double-stranded DNA which has a promoter sequence and is capable of being transcribed into an RNA consisting of the specific base sequence or a sequence complementary to the specific base sequence by using the target RNA as the template, a step of forming an RNA transcript consisting of the specific base sequence or a sequence complementary to the specific base sequence by using an RNA polymerase and a step of forming the double-stranded DNA by using the RNA transcript as the template, in the presence of adenosine triphosphate, uridine triphosphate, cytidine triphosphate, guanosine triphosphate and ITP as the substrates of the RNA polymerase.

The invention ~~defined~~ described in ~~Claim 2~~ of the present application provides the amplification method according to ~~Claim 1~~ the instant invention, wherein RNA polymerase from phage SP6 is used as the RNA polymerase, and inosine triphosphate is added to a final concentration of from 0.5 mM to 2 mM in the amplification procedure. The invention ~~defined~~ described in ~~Claim 3~~ of the present application provides the amplification method according to ~~Claim 2~~ the instant invention, wherein the ratio of the final concentration of inosine triphosphate to the final concentration of the other ribonucleoside triphosphates (adenosine triphosphate, uridine triphosphate, cytidine triphosphate and guanosine triphosphate) is from 0.5:1.0 to 1.5:1.0.

The invention ~~defined~~ described in ~~Claim 4~~ of the present application provides the amplification method according to ~~Claim 1~~ the instant invention, wherein in the amplification procedure, tris-HCl buffer (pH 8.5-8.9) is present at a final concentration of from 20 mM to 50 mM,

magnesium chloride is present at a final concentration of from 12 mM to 20 mM, ribonucleoside triphosphates (adenosine triphosphate, uridine triphosphate, cytidine triphosphate and guanosine triphosphate) are present at a final concentration of 3.5 mM to 5.0 mM, RNA polymerase from phase T7 is present as the RNA polymerase, and inosine triphosphate is present at a final concentration of from 1.0 mM to 2.7 mM. The invention ~~defined~~ described in ~~Claim 5~~ of the present application provides the amplification method according to ~~Claim 4~~ the instant invention, wherein the ratio of the final concentration of inosine triphosphate to the final concentration of the other ribonucleoside triphosphates (adenosine triphosphate, uridine triphosphate, cytidine triphosphate and guanosine triphosphate) is from 0.3:1.0 to 0.7:1.0.

The invention ~~defined~~ described in ~~Claim 6~~ of the present application provides the amplification method according to ~~Claim 1~~ the instant invention, wherein in the amplification procedure, tris-HCl buffer (pH 8.5-8.9) is present at a final concentration of from 50 mM to 80 mM, magnesium chloride is present at a final concentration of from 12 mM to 20 mM, ribonucleoside triphosphates (adenosine triphosphate, uridine triphosphate, cytidine triphosphate and guanosine triphosphate) are present at a final concentration of 2.0 mM to 3.5 mM, RNA polymerase from phage T7 is present as the RNA polymerase, and inosine triphosphate is present at a final concentration of from 3.2 mM to 4.4 mM. The invention ~~defined~~ described in ~~Claim 7~~ of the present application provides the amplification method according to ~~Claim 6~~ the instant invention, wherein the ratio of the final concentration of inosine triphosphate to the final concentration of the other ribonucleoside triphosphates (adenosine triphosphate, uridine triphosphate, cytidine triphosphate and guanosine triphosphate) is from 1.0:1.0 to 1.0:1.5.

The invention ~~defined~~ described in ~~Claim 8~~ of the present application provides the amplification method according to ~~Claim 1~~ the instant invention, wherein the RNA amplification procedure uses a primer complementary to the specific base sequence and a primer homologous to the specific base sequence (either of which is a promoter primer having a promoter sequence for the RNA polymerase at the 5' end) and is characterized in that the target RNA is used as the template

to form a single-stranded DNA by the action of an RNA-dependent DNA polymerase, the single-stranded DNA is used as the template for formation of a double-stranded DNA which has a promoter sequence and is capable of being transcribed into an RNA having the specific base sequence or a sequence complementary to the specific base sequence by the action of a DNA-dependent DNA polymerase, the double-stranded DNA is transcribed into an RNA transcript in the presence of the RNA polymerase, and the RNA transcript is used as the template for the subsequent formation of a single-stranded DNA by the RNA-dependent DNA polymerase.

The invention ~~defined~~ described in ~~Claim 9~~ of the present application provides a method of assay of a target nucleic acid which comprises carrying out the amplification procedure ~~as defined in Claim 1 of the instant invention~~ in the presence of a probe labeled with a fluorescent intercalative dye, and monitoring the fluorescence intensity of the reaction solution. The invention ~~defined~~ described in ~~Claim 10~~ of the present application provides the method according to ~~Claim 9~~ the instant invention, wherein the probe labeled with a fluorescent intercalative dye alters its fluorescence upon hybridization with the RNA transcript.